BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Newsletters » BioWorld

BioWorld

Aug. 24, 2011

View Archived Issues

Vivus Adds $45.8M Ahead of Planned Qnexa Resubmission

Mountain View, Calif.-based Vivus Inc. priced a registered direct offering of 6.9 million shares at $6.65 each for gross proceeds of $45.8 million to boost its balance sheet and support ongoing work with obesity drug Qnexa (phentermine/topiramate), including the resubmission of a new drug application (NDA) expected next quarter. Read More

Fibrocell Brings in $22.8M to Launch Injectable laViv in U.S.

On Tuesday, Fibrocell Science Inc. appeared to swim against the tide of nervous capital markets, raising $22.8 million through a private placement of 41,409,458 shares of common stock at a purchase price of 55 cents per share. Read More

Serotonin-Activated Kinase Can Fight Amyloid Plaques

The road to developing Alzheimer's drugs has been littered with disappointments. But this week, researchers from Washington University in St. Louis published data suggesting that another class of drugs may be useful in preventing the formation of amyloid plaques: antidepressants that work via selective serotonin reuptake inhibition (SSRI). Read More

ThromboGenics' Ocriplasmin Filing on Track in Europe, U.S.

Six-month follow-up data from ThromboGenics NV's Phase III program for its ophthalmology drug Ocriplasmin (microplasmin) confirm top-line data it reported last year and keep the drug on track for a regulatory filing in the coming weeks. Read More

Stock Movers

Read More

Other News To Note

• Cel-Sci Corp., of Vienna, Va., inked a sales, marketing and distribution agreement granting IDC-GP Pharm LLC an exclusive license to cancer therapy Multikine (leukocyte interleukin injection) in Argentina and Venezuela. IDC-GP is a joint venture between two pharmaceutical entrepreneurs with expertise in registration and commercialization in South America. Under the terms, IDC-GP will be responsible for seeking regulatory approval of Multikine and commercializing the drug in its territories, with revenues split 50-50 with Cel-Sci after payment for manufacturing costs. Specific terms were not disclosed. Read More

Clinic Roundup

• PharmaNeuroBoost NV, of Alken, Belgium, received clearance from a U.S.-based institutional review board to begin a Phase III trial with PNB01 for major depression. PNB01 is a combination of the antidepressant citalopram and a low dose of the neuroleptic agent pipamperone. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing